AstraZeneca Pharma shares gain 3% on CDSCO nod for expanded use of cancer drug Imfinzi

Shares of AstraZeneca Pharma India gained as much as 3 percent to Rs 6,890 in afternoon trade on March 3 after the company announced it has secured regulatory approval to expand the use of its cancer therapy, Imfinzi, in the country.

The Central Drugs Standard Control Organisation (CDSCO) has granted the company permission to import, sell, and distribute Durvalumab (Imfinzi) for an additional indication—treating patients with unresectable hepatocellular carcinoma (uHCC), a form of liver cancer.

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients battling advanced-stage liver cancer. While the company still requires other statutory approvals before launching the expanded indication in India, the regulatory green light marks a crucial step in AstraZeneca Pharma’s oncology portfolio expansion.

AstraZeneca Pharma India delivered a stellar performance in Q3FY25, with net profit surging 94.9 percent year-on-year to Rs 30.8 crore, up from Rs 15.8 crore in the same period last year.

Related Posts

  • Pharma
  • July 24, 2025
  • 179 views
Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

  • Pharma
  • July 22, 2025
  • 268 views
DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra